drugset / Trial / NCT00454233

A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects

NCT00454233 ↗

Phase 2 Completed 97 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety of YM543 in type 2 Diabetes Mellitus patients and to investigate whether this study drug is effective in these patients

Timeline

Start
2007-02
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule — Oral
Subject YM543 Small molecule — Oral